Park Avenue Securities LLC boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 64.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,368 shares of the biopharmaceutical company’s stock after buying an additional 538 shares during the period. Park Avenue Securities LLC’s holdings in Alnylam Pharmaceuticals were worth $322,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 3.2% during the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after buying an additional 66,928 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 3.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock valued at $134,035,000 after buying an additional 16,756 shares during the last quarter. Swiss National Bank boosted its holdings in Alnylam Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after purchasing an additional 1,000 shares during the last quarter. Eagle Asset Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 25.7% during the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock worth $85,889,000 after acquiring an additional 63,385 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 0.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 278,241 shares of the biopharmaceutical company’s stock worth $76,525,000 after purchasing an additional 1,294 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the firm’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the sale, the chief marketing officer now directly owns 17,457 shares of the company’s stock, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,372 shares of company stock worth $5,634,205 in the last 90 days. Insiders own 1.50% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on ALNY
Alnylam Pharmaceuticals Trading Up 1.2 %
NASDAQ ALNY opened at $278.76 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a market cap of $35.95 billion, a PE ratio of -106.40 and a beta of 0.34. The company’s 50-day moving average price is $247.13 and its 200-day moving average price is $260.30. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the company earned $1.15 EPS. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Recommended Stories
- Five stocks we like better than Alnylam Pharmaceuticals
- What is the Hang Seng index?
- Bloom Energy: Powering the Future With Decentralized Energy
- Stock Splits, Do They Really Impact Investors?
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.